Amgen and Sanofi are the latest companies to climb on the pay-for-performance bandwagon after reaching agreements with insurer Cigna for their respective cholesterol drugs, Repatha and Praluent.
Under the agreement, the drugmakers will discount the price Cigna pays for their PCSK9 inhibitors if they fail to reduce LDL-C levels at least to the level seen in clinical trials. The original negotiated prices will remain in place if the drugs help to meet or exceed the expected LDL-C reduction.
Cigna spokeswoman Karen Eldred said the company is not disclosing the terms of the deals, such as pricing agreements with the companies and the length of the deals. Sanofi and Amgen did not return requests for comment by press time.